Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

NCI awards Case Western Reserve with $1.6 million grant for cancer research

Case Western Reserve University School of Medicine has received a $1.6 million grant from the National Cancer Institute to study how tumor cells avoid detection by the body's immune system, allowing cancer to develop and spread.

1 Apr 2011

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Spondyloarthritis is a group of inflammatory conditions causing spine and joint pain and deformity, mostly in young men. Important updates on the epidemiology, diagnosis, and treatment of SpA are presented in the April issue of The American Journal of the Medical Sciences, official journal of the Southern Society for Clinical Investigation.

31 Mar 2011

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

31 Mar 2011

Texas Children's Hospital and Baylor College of Medicine create Texas Children's Center for Global Health

Texas Children's Hospital and Baylor College of Medicine (BCM) today announced the creation of the Texas Children's Center for Global Health and the appointment of renowned physician-scientist Dr. Russell E. Ware as director.

31 Mar 2011

Positive outcomes from imatinib trial in both older and younger patients with CML

While the median age at diagnosis for chronic myeloid leukemia is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.

31 Mar 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

Study links genes with alcohol consumption among Asians

In a study of 1,721 Korean male drinkers aged 40󈞱 y in an urban population-based cohort, and another sample of 1,113 male drinkers from an independent rural cohort, information on average daily alcohol consumption was collected and DNA samples were collected for genotyping.

31 Mar 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

Prostate Oncology Specialists introduces new blog for patients

Prostate Oncology Specialists, Inc. announces the launch of the "Prostate Snatchers" blog. It features contributions from a medical oncologist, Mark Scholz MD, who specializes only in prostate cancer and a prostate cancer patient, Ralph H. Blum.

30 Mar 2011

Transgenomic discovers novel BLOCker-Sequencing technology

Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.

30 Mar 2011

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.

29 Mar 2011

Cephalon intends to make takeover bid for ChemGenex

Cephalon, Inc. and ChemGenex Pharmaceuticals Limited today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex.

29 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

New studies demonstrate advantages of Masimo noninvasive and continuous measurements in ICUs

Masimo announced today that three new studies presented at the International Symposium of Intensive Care and Emergency Medicine (ISICEM) Annual Meeting in Brussels, Belgium, demonstrate the accuracy, reliability, and clinical impact of Masimo noninvasive and continuous measurements—noninvasive hemoglobin (SpHb®), Pleth Variability Index (PVI®), and Perfusion Index (PI)—in Intensive Care Unit (ICU) patients.

25 Mar 2011

Gastroenterologist directs new Crohn's and Colitis Program at UT Southwestern

Dorothy Stockstill was taking eight pills a day, and her severe abdominal pain and persistent diarrhea weren't improving. The Denton resident had seen multiple physicians throughout the Dallas area. Her attacks were so severe, she couldn't successfully travel from the front of a retail store to the restrooms in back.

23 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Astellas to acquire all Maxygen's equity interests in Perseid for $76.0 million

Maxygen, Inc. today announced that Astellas Pharma Inc. has exercised its option to purchase all of Maxygen's equity interests in Perseid Therapeutics LLC at the current exercise price of $76.0 million.

17 Mar 2011

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

COMFORT-II, the second pivotal Phase III trial of Incyte Corporation's investigational Janus kinase inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, when compared to best available therapy.

15 Mar 2011

Bayer receives FDA approval for Gadavist Injection

Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist Injection, a macrocyclic gadolinium-based contrast agent, for intravenous use in diagnostic magnetic resonance imaging in adults and children to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.

14 Mar 2011

Hematology News and Research

Further Reading

NCI awards Case Western Reserve with $1.6 million grant for cancer research

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

RXi Pharmaceuticals to acquire Apthera

Texas Children's Hospital and Baylor College of Medicine create Texas Children's Center for Global Health

Positive outcomes from imatinib trial in both older and younger patients with CML

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Study links genes with alcohol consumption among Asians

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Prostate Oncology Specialists introduces new blog for patients

Transgenomic discovers novel BLOCker-Sequencing technology

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Cephalon intends to make takeover bid for ChemGenex

Study finds increased risk of VTE during first year of combination oral contraceptive usage

New studies demonstrate advantages of Masimo noninvasive and continuous measurements in ICUs

Gastroenterologist directs new Crohn's and Colitis Program at UT Southwestern

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Astellas to acquire all Maxygen's equity interests in Perseid for $76.0 million

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

Bayer receives FDA approval for Gadavist Injection

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo